Tirzepatide reduced serum uric acid by up to 0.95 mg/dL over 72 weeks in 2,539 obese adults, with about 73% of the effect driven by the drug's weight loss properties — raising the possibility of gout prevention as an added benefit.
-0.95 mg/dL uric acid reduction at 15mg doseSignificantly greater than placebo (-0.18 mg/dL) over 72 weeks in the SURMOUNT-1 trial, with 72.7% of the effect mediated by weight loss of up to 20.9%
What the researchers found
Tirzepatide treatment over 72 weeks significantly reduced serum uric acid (SUA) at all three dose levels compared to placebo in the SURMOUNT-1 trial of 2,539 adults with obesity. At week 72, SUA decreased by -0.69 mg/dL (5 mg), -0.92 mg/dL (10 mg), and -0.95 mg/dL (15 mg) versus -0.18 mg/dL with placebo (all p<0.001). Reductions were significant regardless of baseline uric acid level or BMI. Mediation analysis showed that weight reduction explained 72.7% of the SUA decrease, suggesting the effect is primarily driven by weight loss (up to 20.9% body weight reduction).
Why it matters
Elevated uric acid causes gout — a painful inflammatory arthritis that frequently co-occurs with obesity. Current gout treatments focus on lowering uric acid with drugs like allopurinol, but they don't address the underlying obesity. Tirzepatide's ability to meaningfully reduce uric acid through weight loss suggests it could help prevent gout flares while simultaneously treating obesity — addressing the root cause rather than just the symptom.
The numbers in context
n=2,539 · 72 weeks · Weight loss up to 20.9% · SUA change: -0.69 (5mg), -0.92 (10mg), -0.95 mg/dL (15mg) vs. -0.18 placebo · All p<0.001 · 72.7% mediated by weight loss
How the study worked
Post hoc analysis of the SURMOUNT-1 randomized, double-blind, placebo-controlled trial. Adults with BMI ≥30 (or ≥27 with complications) were randomized to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Serum uric acid was measured at baseline and multiple time points. Changes were analyzed across dose groups, baseline SUA quartiles, and baseline BMI categories. Mediation analysis quantified how much of the SUA reduction was explained by weight loss.
Who was studied
2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related complications) from the SURMOUNT-1 trial
What this study cannot tell us
This is a post hoc analysis — uric acid reduction was not a prespecified primary outcome of SURMOUNT-1. Participants were not selected for gout or hyperuricemia, so the clinical relevance for gout patients specifically is uncertain. The study did not measure gout flare rates. The remaining 27.3% of SUA reduction not explained by weight loss could reflect direct pharmacological effects, but this was not further investigated.
How to read the evidence
This is a post hoc analysis of a large, well-conducted phase 3 randomized controlled trial (SURMOUNT-1). While the parent trial is high-quality (n=2,539, placebo-controlled, 72 weeks), the uric acid analysis was not a prespecified endpoint, making the findings hypothesis-generating rather than definitive.
When this study was published
Published in 2026, this analysis leverages data from one of the most impactful obesity trials of recent years. The SURMOUNT program established tirzepatide as a leading obesity treatment, and secondary analyses like this one continue to reveal additional clinical benefits.
The bigger picture
Gout is the most common form of inflammatory arthritis, and its prevalence is rising alongside the obesity epidemic. The dual GLP-1/GIP agonist tirzepatide is already reshaping obesity treatment, and this analysis adds uric acid reduction to its growing list of beyond-weight-loss benefits. As more data emerges on the pleiotropic effects of incretin-based peptide drugs, they are increasingly positioned as multi-disease treatments rather than single-indication medications.
Questions still open
- Would tirzepatide reduce actual gout flare rates in patients with established gout and obesity?
- What accounts for the ~27% of SUA reduction not explained by weight loss — direct renal or metabolic effects of tirzepatide?
- How does tirzepatide's uric acid-lowering effect compare to dedicated urate-lowering therapies like allopurinol or febuxostat?
Common questions
What is tirzepatide and how does it differ from semaglutide?
Could tirzepatide replace gout medication?
Read the original research
Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
Annals of the rheumatic diseases, 85(3), 558-565
Citation
Sattar, Naveed; Scilletta, Sabrina; Stefanski, Adam; Wang, Hui; Daly, Jack W; Linetzky, Bruno. (2026). Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.. Annals of the rheumatic diseases, 85(3), 558-565. https://doi.org/10.1016/j.ard.2025.10.009